Please assess the completion status of the following clinical trial:

Trial Title: Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathological diagnosis of classical Hodgkin lymphoma~* Failed standard front-line therapy~* Measurable disease of at least 1.5 cm as documented by radiographic technique~* Eastern Cooperative Oncology Group performance status less than or equal to 2~Exclusion Criteria:~* Received prior salvage therapy, including radiotherapy~* Chemotherapy, radiotherapy, biologics, and/or other treatment with immunotherapy not completed 4 weeks prior to first dose of study drug~* Concurrent use of other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab Vedotin + Bendamustine (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).